查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008771

治療性疫苗市場報告：按類型、疾病、技術、分銷管道和地區分類（2026-2034 年）

Therapeutic Vaccines Market Report by Type, Disease Type, Technology, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球治療性疫苗市場規模達374億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到785億美元，2026年至2034年的複合年成長率（CAGR）為8.32%。北美是推動市場成長的主要地區，這主要得益於治療選擇有限的疾病日益普遍以及技術的進步。微創手術（MIS）的日益普及以及製藥公司、研究機構和學術界之間合作的不斷加強，都是提升市場佔有率的關鍵因素。

治療性疫苗（也稱為免疫療法疫苗）是一種旨在刺激患者自體免疫系統對抗特定疾病的醫療介入。與化療等傳統治療方法相比，治療性疫苗的副作用較少。它們能在不損傷健康細胞的情況下刺激免疫系統，並有助於降低初始治療後疾病復發的可能性。此外，治療性疫苗還可以與其他治療方法（如化療和標靶治療）合併使用，產生協同效應。在治療人類免疫力缺乏病毒（HIV）和B型肝炎等慢性感染疾病方面，治療性疫苗可透過增強免疫反應來抑制病毒量並延緩疾病進展。

某些癌症和罕見疾病等治療手段有限的疾病日益普遍，推動了對疫苗等創新療法的需求。此外，人口老化加劇了對各種慢性疾病的易感性，也增加了對治療性疫苗等新型治療方法的需求。世界各國政府都在為免疫療法和疫苗領域的研發提供支持性政策、津貼和資金。此外，人們越來越傾向於選擇非侵入性或微創治療方法，也推動了對治療性疫苗的需求。製藥公司、研究機構和學術界之間的合作也正在加速治療性疫苗的研發和商業化。

治療性疫苗市場趨勢：

癌症負擔加重

傳統的治療方法，例如化療和放射線治療，往往毒性較大且長期療效有限，因此，日益嚴重的全球癌症負擔成為推動市場擴張的主要動力。根據印度醫學研究理事會（ICMR）預測，到2025年，癌症患者人數將比2020年增加12.8%。隨著生活方式的改變、人口老化和環境因素導致癌症病例增加，人們對副作用更少、療效更持久的創新治療方法的需求日益成長。治療性疫苗旨在激活人體免疫系統，識別並標靶化癌細胞，正逐漸成為一種很有前景的選擇。它們能夠補充現有治療方法並預防復發，這是其主要吸引力所在。隨著全球癌症發生率的持續上升，醫療機構和研究機構正將疫苗治療方法列為優先事項，加速了市場投資和應用。

人們對免疫療法的關注度日益提高。

免疫療法作為慢性病和危及生命的疾病的一線治療方案，其日益成長的關注度正在推動市場發展。與直接針對病變細胞的傳統治療方法不同，免疫療法利用患者自身的免疫系統來識別和靶向有害病原體，從而提供更持久的療效和更低的毒性。 2025年9月，由BioNTech及其合作夥伴百時美施貴寶（BMY.N）共同研發的尖端癌症免疫療法在轉移性小細胞肺癌的中期臨床試驗中顯示出令人鼓舞的腫瘤縮小效果。這項II期臨床試驗的結果顯示，在接受BNT327（普米他米）治療的38名受試者中，76.3%的受試者腫瘤縮小，該藥物符合中期分析的標準。治療性疫苗作為免疫促效劑，針對癌細胞、病毒和其他病原體。免疫療法在腫瘤學和感染疾病治療領域的成功應用，使其信譽度不斷提升，從而推動了對基於疫苗的免疫療法的需求。

對個人化醫療的需求日益成長

患者和臨床醫生對針對個別基因和分子特徵的標靶治療的需求日益成長，推動了個人化醫療市場的發展。根據IMARC Group預測，全球精準醫療市場規模預計在2024年達到821億美元。與傳統的、千篇一律的治療方法不同，治療性疫苗可以根據特定的腫瘤抗原或免疫系統突變進行客製化，從而改善治療效果並最大限度地減少副作用。基因組學和生物標記發現的進步使研究人員能夠設計出針對患者獨特生物學特徵的疫苗，為更精準、更有效的治療方法鋪平了道路。這種向個人化的轉變不僅提高了病患滿意度和存活率，也推動了疫苗研發投入的增加。

治療性疫苗市場的主要成長要素：

技術進步

去氧核糖核酸(DNA) 和信使核糖核酸 (mRNA) 疫苗技術的進步，透過加快研發速度、提高療效和拓展應用範圍，為市場帶來了良好的前景。這些平台能夠精確編碼抗原，刺激針對特定疾病（包括癌症和慢性感染疾病）的強效標靶免疫反應。與傳統疫苗不同，DNA 和 mRNA 技術可以快速設計、製造和大規模生產，從而降低成本並縮短研發時間。它們的柔軟性也支持個人化治療的客製化，與精準醫療的發展趨勢高度契合。隨著創新不斷推進，DNA 和 mRNA 疫苗有望開啟新的治療可能性，並推動市場強勁成長和廣泛應用。

擴大生物技術公司與學術機構之間的合作

生物技術公司與學術機構之間日益增多的夥伴關係，透過將前沿科學研究與商業開發專長相結合，正對市場產生積極影響。學術機構通常主導早期發現，例如新型抗原和免疫機制的核准，而生物技術公司則提供臨床試驗、法規核准和商業化所需的資源和基礎設施。此類合作有助於加速創新，縮短產品上市時間，並提高疫苗開發等高度複雜和高風險領域的成功率。此外，這些合作也促進了知識共用、先進技術的獲取以及專業人才的培養。透過整合智力資源和資金，生物技術公司與學術機構的夥伴關係正在建立強大的治療性疫苗候選產品線，顯著推動市場成長。

政府加大對疫苗研發的投入

政府加大對疫苗研發的投入是推動市場成長的主要動力。這是因為公共部門的支持為推動創新研發和臨床試驗提供了必要的資金基礎。已開發經濟體和新興經濟體的政府機構正在投入大量資源，以加強醫療衛生基礎設施建設，促進生物技術創新，並加速慢性病和感染疾病先進治療方法的早期應用。此類資金投入降低了私人公司的風險，促進了合作，並加速了研究成果向市場化產品的轉換。此外，政府主導的措施也有助於制定監管獎勵，改善尖端平台的使用，並促進國際夥伴關係。這種積極的財政和政策支持確保了持續創新和廣泛應用，最終使治療性疫苗成為現代醫療保健策略的重要組成部分。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球治療性疫苗市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 抗原疫苗
  • 樹突細胞疫苗
  • DNA疫苗
  • 癌細胞疫苗

第7章 市場區隔：依疾病類型分類

  • 自體免疫疾病疫苗
  • 成癮疫苗
  • 神經系統疾病疫苗
  • 感染疾病疫苗
  • 其他

第8章 市場區隔：依技術分類

  • 自體疫苗
  • 同型疫苗

第9章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Agenus Inc.
    • Bavarian Nordic
    • CEL-SCI Corporation
    • Dendreon Pharmaceuticals LLC.
    • Emergent BioSolutions
    • GeoVax
    • GSK plc
    • Merck & Co., Inc.
    • Novavax
    • Nykode Therapeutics ASA
    • Pfizer Inc.
    • Phio Pharmaceuticals
    • Sanofi SA
Product Code: SR112026A6496

The global therapeutic vaccines market size reached USD 37.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 78.5 Billion by 2034, exhibiting a growth rate (CAGR) of 8.32% during 2026-2034. North America dominates the market, driven by rising prevalence of diseases with limited treatment options and technological advancements. Increasing preferences for minimally invasive surgeries (MIS) and the growing partnerships between pharmaceutical companies, research institutions, and academia are some of the major factors propelling the market share.

Therapeutic vaccines, also known as treatment vaccines or immunotherapeutic vaccines, are a type of medical intervention designed to stimulate the immune system of patients to target and combat specific diseases. They have fewer side effects compared to traditional treatments like chemotherapy. They stimulate the immune system without causing extensive damage to healthy cells. They help reduce the likelihood of disease recurrence after initial treatment. They can be combined with other treatments, such as chemotherapy or targeted therapies, to create a synergistic effect. They aid in managing chronic infections like human immunodeficiency viruses (HIV) and hepatitis B by enhancing the immune response to control the viral load and minimize disease progression.

The rising prevalence of diseases with limited treatment options, such as certain types of cancers and rare disorders, is catalyzing the demand for innovative therapeutic approaches like vaccines. Additionally, the increasing aging population aging population, which is highly susceptible to various chronic ailments is driving the need for novel treatment modalities like therapeutic vaccines. Apart from this, governments of various countries are offering supportive policies, grants, and funding for research and development (R&D) in the field of immunotherapy and vaccines. Furthermore, the rising preferences of individuals for non-invasive or minimally invasive treatment options are driving the demand for therapeutic vaccines. Moreover, partnerships between pharmaceutical companies, research institutions, and academia are accelerating the development and commercialization of therapeutic vaccines.

THERAPEUTIC VACCINES MARKET TRENDS:

Rising burden of cancer

The growing global burden of cancer is a key factor fueling the expansion of the market, as conventional treatments like chemotherapy and radiation often come with high toxicity and limited long-term effectiveness. According to the Indian Council of Medical Research, a forecasted 12.8% increase in cancer cases is expected by 2025 relative to 2020. With cancer cases rising due to lifestyle changes, aging population, and environmental factors, there is a growing demand for innovative solutions that provide durable responses with fewer side effects. Therapeutic vaccines, crafted to activate the body's immune system to identify and target tumor cells, are emerging as a promising option. Their ability to complement existing therapies and potentially prevent relapse makes them highly attractive. As cancer incidence continues to rise worldwide, healthcare providers and research organizations are prioritizing vaccine-based therapies, thereby accelerating investments and adoption across the market.

Growing focus on immunotherapy

Rising focus on immunotherapy as a frontline approach to treating chronic and life-threatening diseases is driving momentum in the market. Unlike conventional treatments that directly target diseased cells, immunotherapy leverages the patient's immune system to identify and target harmful agents, offering longer-lasting effects and lesser toxicity. In September 2025, a cutting-edge cancer immunotherapy from BioNTech and partner Bristol Myers Squibb (BMY.N) showed promising tumor reduction in a mid-stage trial for small cell lung cancer that was beginning to metastasize. A Phase II trial indicated that 76.3% of the 38 participants receiving the drug BNT327, or pumitamig, who met criteria for an interim analysis experienced a decrease in their tumors. Therapeutic vaccines act as immune stimulants to target cancer cells, viruses, or other disease-causing agents. As immunotherapy is gaining credibility through successful outcomes in oncology and infectious disease management, the demand for vaccine-based immunotherapies is rising.

Increasing personalized medicine demand

Rising demand for personalized medicine is positively influencing the market, as patients and clinicians are seeking targeted treatments tailored to individual genetic and molecular profiles. As per the IMARC Group, the global precision medicine market size reached USD 82.1 Billion in 2024. Unlike traditional one-size-fits-all approaches, therapeutic vaccines can be developed to match specific tumor antigens or immune system variations, enhancing treatment outcomes and minimizing adverse effects. Advancements in genomics and biomarker discovery are enabling researchers to design vaccines that align with patients' unique biological characteristics, paving the way for more precise and effective therapies. This shift towards personalization is not only improving patient satisfaction and survival rates but also attracting higher investments in vaccine research and development (R&D) activities.

KEY GROWTH DRIVERS OF THERAPEUTIC VACCINES MARKET:

Advancements in technology

Advancements in deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) vaccine technology are offering a favorable market outlook by enabling faster development, higher efficacy, and broader application potential. These platforms allow precise encoding of antigens that stimulate strong and targeted immune responses against specific diseases, including cancer and chronic infections. Unlike traditional vaccines, DNA and mRNA technologies can be quickly designed, manufactured, and scaled, reducing both cost and development timelines. Their flexibility also supports customization for personalized therapies, aligning well with the shift towards precision medicine. As innovation continues, DNA and mRNA vaccines are expected to unlock new treatment possibilities, driving robust growth and adoption in the market.

Expanding collaborations between biotech firms and academia

Rising partnerships between biotech firms and academic institutions are positively influencing the market, bridging cutting-edge scientific research with commercial development expertise. Academic institutions often drive early-stage discoveries, such as identifying novel antigens or immune mechanisms, while biotech companies bring the resources and infrastructure needed for clinical trials, regulatory approval, and commercialization. These collaborations aid in accelerating innovations, reducing time-to-market, and enhancing the chances of success in a highly complex and high-risk field like vaccine development. Furthermore, alliances promote knowledge sharing, access to advanced technologies, and training of skilled professionals. By pooling intellectual and financial resources, biotech-academia partnerships are creating a strong pipeline of therapeutic vaccine candidates, significantly advancing the market growth trajectory.

Rising government funding for vaccine development

Increasing government funding for vaccine development is a major driver of the market growth, as public sector support provides the financial backbone needed to advance innovative research and clinical trials. Government agencies across developed and emerging economies are allocating significant resources to strengthen healthcare infrastructure, promote biotechnology innovation, and accelerate the availability of advanced therapies for chronic and infectious diseases. Such funding reduces the risk for private companies, encouraging collaboration and faster translation of discoveries into market-ready products. Moreover, government-backed initiatives help create regulatory incentives, improve access to cutting-edge platforms, and foster international partnerships. This proactive financial and policy support ensures sustained innovations and widespread adoption, ultimately positioning therapeutic vaccines as a vital component of modern healthcare strategies.

THERAPEUTIC VACCINES INDUSTRY SEGMENTATION:

Breakup by Type:

  • Antigen Vaccines
  • Dendritic Cell Vaccine
  • DNA Vaccine
  • Tumor Cell Vaccines

Tumor cell vaccines hold the largest market share

Breakup by Disease Type:

  • Autoimmune Disease Vaccines
  • Addiction Vaccine
  • Neurological Disease Vaccine
  • Infectious Disease Vaccine
  • Others

Autoimmune disease vaccines represent the largest market segment

Breakup by Technology:

  • Autologous Vaccines
  • Allogeneic Vaccine

Autologous vaccines account for the majority of the market share

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Hospital pharmacies operate within healthcare facilities, which ensures direct access to patients undergoing treatments. They facilitate immediate availability, expert guidance, and seamless integration with medical care and aid in dispensing and administering therapeutic vaccines, especially for critical conditions requiring close medical supervision.

Retail pharmacies are widespread and easily accessible to the general population. They offer convenience and a wide range of healthcare products, including therapeutic vaccines. Additionally, they cater to diverse patient needs, making therapeutic vaccines more accessible to the masses.

Online pharmacies offer a convenient platform to purchase therapeutic vaccines remotely. They provide a wide selection, price comparisons, and home delivery, which are particularly advantageous for patients with mobility limitations or those seeking privacy.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest therapeutic vaccines market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share since the region has a well-developed healthcare infrastructure, comprising modern hospitals, research institutions, and pharmaceutical companies, which accelerates research, development, and commercialization of therapeutic vaccines. Additionally, North America is a global hub for medical research and innovation, housing renowned universities, research centers, and biotechnology firms. Apart from this, regulatory agencies in North America, such as the U.S. Food and Drug Administration (FDA) and Health Canada, maintain rigorous standards for drug and vaccine approvals. Moreover, North America has a well-established clinical trial ecosystem, which facilitates the efficient testing and validation of therapeutic vaccines. The availability of diverse patient populations and expert medical professionals expedites the trial process.

COMPETITIVE LANDSCAPE:

Companies are investing in research to identify novel antigens and develop innovative vaccine platforms, which include exploring cutting-edge technologies like mRNA-based vaccines, viral vectors, and personalized vaccine approaches. Additionally, many vaccine developers are conducting rigorous clinical trials to evaluate the safety and efficacy of their products. Furthermore, they are working closely with regulatory agencies to obtain approvals for their therapeutic vaccines. This involves compiling comprehensive data from clinical trials to demonstrate safety, efficacy, and manufacturing quality. Moreover, many leading companies are investing in infrastructure and technologies to ensure consistent and efficient vaccine production.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Agenus Inc.
  • Bavarian Nordic
  • CEL-SCI Corporation
  • Dendreon Pharmaceuticals LLC
  • Emergent BioSolutions
  • GeoVax
  • GSK plc
  • Merck & Co., Inc.
  • Novavax
  • Nykode Therapeutics ASA
  • Pfizer Inc.
  • Phio Pharmaceuticals
  • Sanofi S.A

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global therapeutic vaccines market in 2025?

2. What is the expected growth rate of the global therapeutic vaccines market during 2026-2034?

3. What are the key factors driving the global therapeutic vaccines market?

4. What has been the impact of COVID-19 on the global therapeutic vaccines market?

5. What is the breakup of the global therapeutic vaccines market based on the type?

6. What is the breakup of the global therapeutic vaccines market based on the disease type?

7. What is the breakup of the global therapeutic vaccines market based on the technology?

8. What are the key regions in the global therapeutic vaccines market?

9. Who are the key players/companies in the global therapeutic vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Therapeutic Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Antigen Vaccines
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Dendritic Cell Vaccine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 DNA Vaccine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Tumor Cell Vaccines
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Autoimmune Disease Vaccines
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Addiction Vaccine
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurological Disease Vaccine
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Infectious Disease Vaccine
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Technology

  • 8.1 Autologous Vaccines
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Allogeneic Vaccine
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Agenus Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bavarian Nordic
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 CEL-SCI Corporation
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Dendreon Pharmaceuticals LLC.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Emergent BioSolutions
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 GeoVax
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 GSK plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck & Co., Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novavax
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Nykode Therapeutics ASA
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Pfizer Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Phio Pharmaceuticals
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Sanofi S.A
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Therapeutic Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Therapeutic Vaccines Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Therapeutic Vaccines Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Therapeutic Vaccines Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Therapeutic Vaccines Market: Breakup by Disease Type (in %), 2025
  • Figure 6: Global: Therapeutic Vaccines Market: Breakup by Technology (in %), 2025
  • Figure 7: Global: Therapeutic Vaccines Market: Breakup by Distribution Channel (in %), 2025
  • Figure 8: Global: Therapeutic Vaccines Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Therapeutic Vaccines (Antigen Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Therapeutic Vaccines (Antigen Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Therapeutic Vaccines (Dendritic Cell Vaccine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Therapeutic Vaccines (Dendritic Cell Vaccine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Therapeutic Vaccines (DNA Vaccine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Therapeutic Vaccines (DNA Vaccine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Therapeutic Vaccines (Tumor Cell Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Therapeutic Vaccines (Tumor Cell Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Therapeutic Vaccines (Autoimmune Disease Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Therapeutic Vaccines (Autoimmune Disease Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Therapeutic Vaccines (Addiction Vaccine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Therapeutic Vaccines (Addiction Vaccine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Therapeutic Vaccines (Neurological Disease Vaccine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Therapeutic Vaccines (Neurological Disease Vaccine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Therapeutic Vaccines (Infectious Disease Vaccine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Therapeutic Vaccines (Infectious Disease Vaccine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Therapeutic Vaccines (Other Disease Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Therapeutic Vaccines (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Therapeutic Vaccines (Autologous Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Therapeutic Vaccines (Autologous Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Therapeutic Vaccines (Allogeneic Vaccine) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Therapeutic Vaccines (Allogeneic Vaccine) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Therapeutic Vaccines (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Therapeutic Vaccines (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Therapeutic Vaccines (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Therapeutic Vaccines (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Therapeutic Vaccines (Online Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Therapeutic Vaccines (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: North America: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: North America: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: United States: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: United States: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Canada: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Canada: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Asia-Pacific: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Asia-Pacific: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: China: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: China: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Japan: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Japan: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: India: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: India: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: South Korea: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: South Korea: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Australia: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Australia: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Indonesia: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Indonesia: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Others: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Others: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Europe: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Europe: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Germany: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Germany: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: France: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: France: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: United Kingdom: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: United Kingdom: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Italy: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Italy: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Spain: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Spain: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Russia: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Russia: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Latin America: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Latin America: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Brazil: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Brazil: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Mexico: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Mexico: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Others: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Others: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Middle East and Africa: Therapeutic Vaccines Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Middle East and Africa: Therapeutic Vaccines Market: Breakup by Country (in %), 2025
  • Figure 85: Middle East and Africa: Therapeutic Vaccines Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Global: Therapeutic Vaccines Industry: SWOT Analysis
  • Figure 87: Global: Therapeutic Vaccines Industry: Value Chain Analysis
  • Figure 88: Global: Therapeutic Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Therapeutic Vaccines Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Therapeutic Vaccines Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Therapeutic Vaccines Market Forecast: Breakup by Disease Type (in Million USD), 2026-2034
  • Table 4: Global: Therapeutic Vaccines Market Forecast: Breakup by Technology (in Million USD), 2026-2034
  • Table 5: Global: Therapeutic Vaccines Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 6: Global: Therapeutic Vaccines Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Therapeutic Vaccines Market: Competitive Structure
  • Table 8: Global: Therapeutic Vaccines Market: Key Players